We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more


Key Insights from March 2018 ACC: CLEAR Outcomes Looking Even CLEARer After ODYSSEY – Updated ICER Cost-Effectiveness Analysis A Win for Patients and for the Bempedoic Acid Franchise

Our Lipid Management Team attended the 67th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando this… more

Posted by mlowe@esperion.com

Help with Understanding Liver Function Test Increases: From the Lipid Management Team

We recently announced positive results from our first pivotal phase 3 study (Study 4 or the 048 study) of bempedoic… more

Posted by mlowe@esperion.com

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Future of Cholesterol Lowering Treatments

In Part I and Part II of this series we explored the evolution of LDL-cholesterol: from the early days of… more

Posted by mlowe@esperion.com